Valverde, Claudia

Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial

Martin-Broto, J., Hindi, N., Grignani, G., Martinez-Trufero, J., Redondo, A., Valverde, C., Stacchiotti, S., Lopez-Pousa, A., D'Ambrosio, L., Gutierrez, A., et al. (2020) · Journal for ImmunoTherapy of Cancer

Sarcoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 183

RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas

Serrano, C., Romagosa, C., Hernández‐Losa, J., Simonetti, S., Valverde, C., Moliné, T., Somoza, R., Pérez, M., Vélez, R., Vergés, R., et al. (2016) · Cancer

Sarcoma Diagnosis and TreatmentPI3K/AKT/mTOR signaling in cancer

Cited by 59

Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).

McCabe, M., Kirton, L., Khan, M., Fenwick, N., Strauss, S. J., Valverde, C., Mata, C., Gaspar, N., Luksch, R., Longhi, A., et al. (2022) · Journal of Clinical Oncology

Sarcoma Diagnosis and TreatmentAcute Lymphoblastic Leukemia research

Cited by 46

Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial

Palmerini, E., Lopez Pousa, A., Grignani, G., Redondo, A., Hindi, N., Provenzano, S., Sebio, A., Lopez Martin, J. A., Valverde, C., Martinez Trufero, J., et al. (2025) · Cancer

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 29

Impact of immune-related adverse events on survival in patients with metastastic urothelial carcinoma treated with immune-checkpoint inhibitors.

Morales-Barrera, R., Suarez Rodriguez, C., Gonzalez, M., Ros, J., Semidey, M. E., Serra Hernandez, E., Mateo, J., Fernández Sáez, C., Lozano, F., Mast, R., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments

Cited by 10